US › Healthcare

In8bio Inc (INAB)

US · Healthcare · Biotechnology

$0.96+0.01%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-5.1M
Profit YoY
+8.3%
EPS
$-0.26
EPS estimate
$-0.69

EPS came in at -0.26 against a street estimate of -0.69 — a beat of 62.3%.

Key statistics

Market cap
$9.9M
Forward P/E
0.0
P/B
0.45
Book value
$2.31
EPS (TTM)
$-2.54
52-week high
$2.73
52-week low
$0.94
50-day MA
$1.42
200-day MA
$1.70
Beta
0.22

Analyst view

Analysts rate In8bio Inc a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $6.25.

Shareholding

Insiders
13.40%
Institutions
38.11%

Largest institutional holders

FundStake
Alyeska Investment Group, L.P.9.85%
Franklin Resources Inc9.54%
683 Capital Management LLC7.56%
Stonepine Capital Management Llc6.92%
BIOS CAPITAL MANAGEMENT, LP1.75%
Vanguard Capital Management, LLC0.93%
Geode Capital Management, LLC0.90%
Vanguard Fiduciary Trust Co0.45%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for In8bio Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.